Latest News and Press Releases

SAN DIEGO, CA, March 09, 2021 (GLOBE NEWSWIRE) -- Emerald Health Pharmaceuticals Inc. (EHP, or, the Company), a clinical-stage biotechnology company developing a new class of medicines to treat...

SAN DIEGO, CA, March 08, 2021 (GLOBE NEWSWIRE) -- Emerald Health Pharmaceuticals Inc. (EHP or the Company), a clinical-stage biotechnology company developing a new class of medicines to treat...

Data published in peer-reviewed journal, Molecular and Cellular Neuroscience, show neuroprotective and neurogenic activity of proprietary product candidate, EHP-102 SAN DIEGO, CA, Feb. 09, 2021 ...

New round will open on December 7, 2020 and close on or before March 28, 2021 SAN DIEGO, CA, Dec. 03, 2020 (GLOBE NEWSWIRE) -- Emerald Health Pharmaceuticals Inc. (EHP), a clinical-stage...

SAN DIEGO, CA, Oct. 19, 2020 (GLOBE NEWSWIRE) -- Emerald Health Pharmaceuticals Inc. (EHP), a clinical-stage biotechnology company developing a new class of medicines to treat diseases with unmet...

SAN DIEGO, CA, July 27, 2020 (GLOBE NEWSWIRE) -- Emerald Health Pharmaceuticals Inc. (EHP), a clinical-stage biotechnology company developing a new class of medicines to treat diseases with unmet...

SAN DIEGO, CA, July 20, 2020 (GLOBE NEWSWIRE) -- Emerald Health Pharmaceuticals Inc. (EHP), a clinical-stage biotechnology company developing a new class of medicines to treat diseases with unmet...

Enrollment open in systemic sclerosis study of novel lead product candidate SAN DIEGO, CA, May 28, 2020 (GLOBE NEWSWIRE) -- Emerald Health Pharmaceuticals Inc. (EHP), a clinical-stage biotechnology...

Novel product candidate, EHP-101, has received Orphan designation and demonstrated a unique multi-pronged mechanism of action related to the treatment of systemic sclerosis SAN DIEGO, CA, March ...

The same previous designation by the US Drug Enforcement Administration alleviates the typical complexities associated with developing controlled substances throughout North America SAN DIEGO,...